These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 24989913)

  • 21. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
    Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
    Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological profile and receptor status in breast carcinoma: an institutional study.
    Rao C; Shetty J; Kishan Prasad HL
    J Cancer Res Ther; 2013; 9(1):44-9. PubMed ID: 23575073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
    Shahi KS; Bhandari G; Singh A
    J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
    Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
    Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
    Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
    Wang SY; Peng DF; Cai ZG; Zhang RZ; Yao TJ; Zhang H; Yang M; Dong HM
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):203-6. PubMed ID: 18756937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression and significance of phosphorylated Girdin in breast cancer].
    Xu Y; Fu L; Gu F; Ma YJ
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of predictive factors affecting sentinel lymph node status in early breast cancer patients].
    Jiao D; Qiao J; Lu Z; Li L; Zhang H; Liu H; Cui S; Liu Z
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):198-201. PubMed ID: 24785280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation between Tau expression and clinicopathological characteristics of breast invasive ductal carcinomas].
    Fan XQ; Xiong QY; Tu JH; Lei QM; DU ZM
    Zhonghua Yi Xue Za Zhi; 2013 Apr; 93(16):1258-60. PubMed ID: 23902620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
    Meng J; Lang RG; Fan Y; Fu L
    Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.